General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery

Study Purpose

In partnership with Helmsley Charitable Trust, the Sanford PLEDGE Study is a large-scale, observational, feasibility study of general population screening for T1D and celiac autoantibodies. Screening is incorporated into routine health care visits within an integrated health system.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Yes
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 0 Minutes - 17 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Newborn Entry: Viable, term infants, defined as 36 weeks gestation by either dates or ultrasound who are born to pregnant women, 18 years or older, who are willing and able to provide informed consent (IC) prior to the onset of active labor.
Who are born at a Sanford Health Hospital and plan to have routine well-child care at a Sanford Clinic.
  • - Pediatric Entry: Children less than 6 years of age who receive their routine care at a Sanford facility and whose parents are able to provide IC.
  • - Adolescent Entry: Children, ages 9-16 years old, who receive their routine care at a Sanford facility and whose parents are able to provide IC.
  • - Siblings of children known to have T1D-relevant antibodies; ages 6 to 17 years old.
  • - Who receive care at a Sanford clinic.
  • - Have an active MyChart account (with proxy access).

Exclusion Criteria:

  • - Subject is in the opinion of the investigator, unable to comply with the requirements of the study protocol.
- Children known to have T1D

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04477928
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Sanford Health
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Kurt Griffin, PhD, MD
Principal Investigator Affiliation Sanford Research
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Type 1 Diabetes, Celiac Disease
Additional Details

Most children with type 1 diabetes (T1D) do not have a family member with diabetes and often are not diagnosed until the child is very sick. Research suggests that screening and identifying children at risk for T1D autoantibodies can prevent serious illness at the time of diagnosis and improve long-term health outcomes. The investigators will screen children, ages 0-5.99 or 9-16 years for blood markers related to T1D and celiac disease during routine healthcare delivery at birth, 1, 2 and 5 years, or once between 9 and 16 years of age. Children with confirmed autoantibodies will be offered participation in other monitoring or prevention trials (T1D), or referred to clinical care (celiac).

Arms & Interventions

Arms

: Study Group

Children receiving routine primary care at a Sanford facility

Interventions

Diagnostic Test: - Sera and whole blood sampling

Study Entry: Single Nucleotide Polymorphism (SNP)-Based Genetic Risk Score at study entry. 2 years old: T1D autoantibodies, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibodies 5 years old: T1D and celiac autoantibodies 9-16 year old: one-time T1D and celiac autoantibodies Siblings of people with T1D autoimmunity, ages 6-17 years: one-time T1D and celiac autoantibodies

Diagnostic Test: - Differential Gene Expression (DGE)

Opt-in: Differential Gene Expression from cord blood at birth and peripheral blood at 12 months of age

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Sanford Bemidji Region Clinics, Bemidji, Minnesota

Status

Recruiting

Address

Sanford Bemidji Region Clinics

Bemidji, Minnesota, 56601

Site Contact

Ann Mays, RN, CPN

ann.mays@sanfordhealth.org

605-312-6052

Sanford Bismarck Region Clinics, Bismarck, North Dakota

Status

Recruiting

Address

Sanford Bismarck Region Clinics

Bismarck, North Dakota, 58501

Site Contact

Ann Mays, RN, CPN

ann.mays@sanfordhealth.org

605-312-6052

Sanford Fargo Region Clinics, Fargo, North Dakota

Status

Recruiting

Address

Sanford Fargo Region Clinics

Fargo, North Dakota, 58112

Sanford Sioux Falls Region Clinics, Sioux Falls, South Dakota

Status

Recruiting

Address

Sanford Sioux Falls Region Clinics

Sioux Falls, South Dakota, 57105

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

PO Box 544, Ambler, PA 19002

Phone: 215-325-1306

Toll-Free: 844-856-6692

Press Room / Media Inquiries

Contact Information

The information found on this website is not intended to be a replacement or substitute for professional medical treatment or for professional medical advice relative to a specific medical condition. We urge you to always seek the advice of your physician. There is no replacement for personal medical treatment and advice from your personal physician.